A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Atrial Fibrillation
Спонсор: Janssen Research & Development, LLC
Налично на:
БГ
Обобщение
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Кой може да участва
Inclusion Criteria:
* Minimum age of 18 years
* Medically stable and appropriate for chronic antithrombotic treatment
* Atrial fibrillation eligible to receive anticoagulation
* Participant must satisfy one or both of the following categories of risk factors (a or b): a) one or more of the following risk factors: i) age greater than or equal to 75 years, ii) history of any type of stroke including symptomatic stroke of any kind. b) two or more of the following risk factors: i) age between 65 and 74 years, ii) hypertension, iii) diabetes mellitus, iv) atherosclerotic vascular disease, v) heart failure
Exclusion Criteria:
* Hemodynamically significant valve disease or those with valve disease that will potentially require surgical valve replacement during the study
* Any condition other than AF that requires chronic anticoagulation
Места на провеждане
37
Argentina (1)
Instituto de Investigaciones Clinicas Bahia Blanca
Bahía Blanca
Австралия (1)
Flinders Medical Centre
Adelaide
Белгия (1)
Algemeen Stedelijk Ziekenhuis
Aalst
Бразилия (1)
Hospital Felício Rocho
Belo Horizonte
България (1)
MHAT Puls
Blagoevgrad
Канада (1)
The Governers of the University of Calgary
Calgery , Alberta
Chile (1)
Quantum Research
Puerto Varas
Китай (1)
Beijing Anzhen Hospital, Capital Medical University
БГ
EN